Matches in SemOpenAlex for { <https://semopenalex.org/work/W3140697131> ?p ?o ?g. }
- W3140697131 abstract "Cystic fibrosis is a genetic disorder in which abnormal mucus in the lungs is associated with susceptibility to persistent infection. Pulmonary exacerbations are when symptoms of infection become more severe. Antibiotics are an essential part of treatment for exacerbations and inhaled antibiotics may be used alone or in conjunction with oral antibiotics for milder exacerbations or with intravenous antibiotics for more severe infections. Inhaled antibiotics do not cause the same adverse effects as intravenous antibiotics and may prove an alternative in people with poor access to their veins. This is an update of a previously published review.To determine if treatment of pulmonary exacerbations with inhaled antibiotics in people with cystic fibrosis improves their quality of life, reduces time off school or work and improves their long-term survival.We searched the Cochrane Cystic Fibrosis Group's Cystic Fibrosis Trials Register. Date of the last search: 03 October 2018.We searched ClinicalTrials.gov, the Australia and New Zealand Clinical Trials Registry and WHO ICTRP for relevant trials. Date of last search: 09 October 2018.Randomised controlled trials in people with cystic fibrosis with a pulmonary exacerbation in whom treatment with inhaled antibiotics was compared to placebo, standard treatment or another inhaled antibiotic for between one and four weeks.Two review authors independently selected eligible trials, assessed the risk of bias in each trial and extracted data. They assessed the quality of the evidence using the GRADE criteria. Authors of the included trials were contacted for more information.Four trials with 167 participants are included in the review. Two trials (77 participants) compared inhaled antibiotics alone to intravenous antibiotics alone and two trials (90 participants) compared a combination of inhaled and intravenous antibiotics to intravenous antibiotics alone. Trials were heterogenous in design and two were only available in abstract form. Risk of bias was difficult to assess in most trials, but for all trials we judged there to be a high risk from lack of blinding and an unclear risk with regards to randomisation. Results were not fully reported and only limited data were available for analysis.Inhaled antibiotics alone versus intravenous antibiotics aloneOnly one trial (n = 18) reported a perceived improvement in lifestyle (quality of life) in both groups (very low-quality of evidence). Neither trial reported on time off work or school. Both trials measured lung function, but there was no difference reported between treatment groups (very low-quality evidence). With regards to our secondary outcomes, one trial (n = 18) reported no difference in the need for additional antibiotics and the second trial (n = 59) reported on the time to next exacerbation. In neither case was a difference between treatments identified (both very low-quality evidence). The single trial (n = 18) measuring adverse events and sputum microbiology did not observe any in either treatment group for either outcome (very low-quality evidence).Inhaled antibiotics plus intravenous antibiotics versus intravenous antibiotics aloneNeither trial reported on quality of life or time off work or school. Both trials measured lung function, but found no difference between groups in forced expiratory volume in one second (one trial, n = 28, very low-quality evidence) or vital capacity (one trial, n = 62). Neither trial reported on the need for additional antibiotics or the time to the next exacerbation; however, one trial (n = 28) reported on hospital admissions and found no difference between groups. Both trials reported no difference between groups in adverse events (very low-quality evidence) and one trial (n = 62) reported no difference in the emergence of antibiotic-resistant organisms (very low-quality evidence).There is little useful high-level evidence to judge the effectiveness of inhaled antibiotics for the treatment of pulmonary exacerbations in people with cystic fibrosis. The included trials were not sufficiently powered to achieve their goals. Hence, we are unable to demonstrate whether one treatment was superior to the other or not. Further research is needed to establish whether inhaled tobramycin may be used as an alternative to intravenous tobramycin for some pulmonary exacerbations." @default.
- W3140697131 created "2021-04-13" @default.
- W3140697131 creator A5015400131 @default.
- W3140697131 creator A5016784895 @default.
- W3140697131 creator A5071649721 @default.
- W3140697131 date "2018-10-30" @default.
- W3140697131 modified "2023-09-26" @default.
- W3140697131 title "Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis" @default.
- W3140697131 cites W1020897773 @default.
- W3140697131 cites W1045435217 @default.
- W3140697131 cites W137803055 @default.
- W3140697131 cites W1521667132 @default.
- W3140697131 cites W1583781357 @default.
- W3140697131 cites W1877333999 @default.
- W3140697131 cites W1904652721 @default.
- W3140697131 cites W1963659111 @default.
- W3140697131 cites W1964548829 @default.
- W3140697131 cites W1965776060 @default.
- W3140697131 cites W1966248805 @default.
- W3140697131 cites W1969513747 @default.
- W3140697131 cites W1969789796 @default.
- W3140697131 cites W1971133935 @default.
- W3140697131 cites W1971308436 @default.
- W3140697131 cites W1971937804 @default.
- W3140697131 cites W1972714977 @default.
- W3140697131 cites W1975379303 @default.
- W3140697131 cites W1977640666 @default.
- W3140697131 cites W1979329224 @default.
- W3140697131 cites W1979652514 @default.
- W3140697131 cites W1979704575 @default.
- W3140697131 cites W1981085645 @default.
- W3140697131 cites W1983565407 @default.
- W3140697131 cites W1987865402 @default.
- W3140697131 cites W1989841457 @default.
- W3140697131 cites W1990312546 @default.
- W3140697131 cites W1990698756 @default.
- W3140697131 cites W1990717609 @default.
- W3140697131 cites W1993019338 @default.
- W3140697131 cites W1996215008 @default.
- W3140697131 cites W1996632302 @default.
- W3140697131 cites W1998612252 @default.
- W3140697131 cites W1999435300 @default.
- W3140697131 cites W1999595197 @default.
- W3140697131 cites W1999729335 @default.
- W3140697131 cites W2000030457 @default.
- W3140697131 cites W2006634231 @default.
- W3140697131 cites W2006762323 @default.
- W3140697131 cites W2008210155 @default.
- W3140697131 cites W2008586082 @default.
- W3140697131 cites W2009812539 @default.
- W3140697131 cites W2010268034 @default.
- W3140697131 cites W2010865348 @default.
- W3140697131 cites W2013235350 @default.
- W3140697131 cites W2014673448 @default.
- W3140697131 cites W2015944029 @default.
- W3140697131 cites W2016806157 @default.
- W3140697131 cites W2018392439 @default.
- W3140697131 cites W2020334178 @default.
- W3140697131 cites W2023428643 @default.
- W3140697131 cites W2023504710 @default.
- W3140697131 cites W2024545486 @default.
- W3140697131 cites W2027723289 @default.
- W3140697131 cites W2028274288 @default.
- W3140697131 cites W2029144761 @default.
- W3140697131 cites W2029955786 @default.
- W3140697131 cites W2032147058 @default.
- W3140697131 cites W2033172874 @default.
- W3140697131 cites W2033895820 @default.
- W3140697131 cites W2034083161 @default.
- W3140697131 cites W2034188416 @default.
- W3140697131 cites W2034964508 @default.
- W3140697131 cites W2035354851 @default.
- W3140697131 cites W2035425516 @default.
- W3140697131 cites W2037494793 @default.
- W3140697131 cites W2037533817 @default.
- W3140697131 cites W2039936290 @default.
- W3140697131 cites W2040567526 @default.
- W3140697131 cites W2042222169 @default.
- W3140697131 cites W2042602096 @default.
- W3140697131 cites W2043806515 @default.
- W3140697131 cites W2044393875 @default.
- W3140697131 cites W2046121684 @default.
- W3140697131 cites W2046513922 @default.
- W3140697131 cites W2046529062 @default.
- W3140697131 cites W2047992616 @default.
- W3140697131 cites W2049260196 @default.
- W3140697131 cites W2050372767 @default.
- W3140697131 cites W2052197420 @default.
- W3140697131 cites W2053220154 @default.
- W3140697131 cites W2055857822 @default.
- W3140697131 cites W2055954317 @default.
- W3140697131 cites W2058103582 @default.
- W3140697131 cites W2058345093 @default.
- W3140697131 cites W2066219884 @default.
- W3140697131 cites W2066814300 @default.
- W3140697131 cites W2068781163 @default.
- W3140697131 cites W2070458418 @default.
- W3140697131 cites W2070733893 @default.
- W3140697131 cites W2071034664 @default.
- W3140697131 cites W2073623971 @default.